SAVA
Cassava Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SAVA
Cassava Sciences, Inc.
A clinical-stage biotechnology company focused on Alzheimer’s disease
6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731
--
Cassava Sciences, Inc., is a biopharmaceutical company dedicated to the development of new drugs. The company's main drug candidate is called oxycodone (oxycodone) sustained-release capsules. Oxycodone is a powerful pain reliever, and its unique formulation helps reduce the potential threat of unplanned doses. Oxycodone and three other non-abuse painkillers were developed in cooperation with King Pharmaceuticals, Inc., and under a license agreement (Pfizer Agreements). King Pharma, Inc., is a subsidiary of Pfizer, Inc. The company was incorporated in Delaware in May 1998.
Company Financials
EPS
SAVA has released its 2025 Q3 earnings. EPS was reported at -0.22, versus the expected -0.27, beating expectations. The chart below visualizes how SAVA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
